<DOC>
	<DOCNO>NCT02201550</DOCNO>
	<brief_summary>The purpose study determine effect exogenous glucagon-like peptide-1 immune system i.e regulation immune cell important disease obesity diabetes . The hypothesis : - Glucagon-like peptide-1 immunological effect observe study immune cell blood - Treatment glucagon-like peptide-1 increase number immune cell blood - Treatment glucagon-like peptide-1 lead anti-inflammatory cytokine profile blood</brief_summary>
	<brief_title>Study Immune Cells Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes BMI &gt; 27 kg/m2 Planed start treatment liraglutide Age &gt; 18 year Infection active inflammatory disorder Immunomodulating treatment ( i.e nonsteroidal antiinflammatory drug , glucocorticoid ) Smoking Alcohol consumption &gt; 14 beverages/week Former bariatric surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>